PlainBillCongress, translated.Legislation. Context. Public interest.Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Congressional Research Service
Version 00 · Introduced in House · Nov 5, 1999
Drug Import Fairness Act of 1999 - Amends the Federal Food, Drug, and Cosmetic Act (FDCA) to prohibit the Secretary of Health and Human Services, with regard to a drug being imported or offered for import, from sending a notice to a person suggesting that importing the drug is, or appears to be, in violation of the FDCA unless: (1) the Secretary determines the drug is adulterated, misbranded, in violation of FDCA provisions relating to new drugs, the drug is forbidden or restricted in sale in the producing or exporting country, importation by any person other than the manufacturer violates reimportation provisions, or the importation otherwise violates Federal law; (2) the notice does not specify any provision described in the provisions of this act relating to those determinations that is not applicable to the drug's importation; and (3) the notice states the underlying reasons for the determination.
People & committees
Rep. Gutknecht, Gil [R-MN-1] · R–MN
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5426-5427)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H5426-5427)
DEBATE - The House resumed debate on H.R. 3240.
DEBATE - The House proceeded with forty minutes of debate on H.R. 3240.
Considered under suspension of the rules. (consideration: CR H5426-5434)
Mr. Bilbray moved to suspend the rules and pass the bill.
Sponsor introductory remarks on measure. (CR H2096-2097)
Sponsor introductory remarks on measure. (CR H360-361)
Referred to the Subcommittee on Health and Environment.
Referred to the House Committee on Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Jun 3, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.3240 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.3240 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.3240 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.3240 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.